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Abstract
Background Opioids are commonly prescribed after laparoscopic bariatric surgery but have untoward effects including
dependence and diversion. Prior investigation revealed that over three-fourths of discharge opioids prescribed to our patients
went unused.
Objectives To determine the feasibility of an opioid sparing discharge protocol following laparoscopic bariatric surgery.
Methods A total of 212 opioid-naïve patients undergoing laparoscopic bariatric surgery were examined and divided into
two groups; 106 prior to (Cohort A) and 106 after implementation of an opioid sparing discharge protocol (Cohort B). Opioids were converted to morphine milligram equivalents (MME) and post-operative consumption was examined. Data was
described as mean ± standard deviation.
Results No patients in Cohort B and 54.7% (58) in Cohort A received an opioid discharge prescription (37.5 MME). Of
the 154 patients that remained, only 1.3% (2) received one after discharge. Cohort A took greater amounts of opioids than
Cohort B after discharge (4.74 ± 11 vs. 0.21 ± 2 MME; p < 0.001). During hospitalization, Cohort A took greater amounts
of opioids (6.92 ± 11 vs. 2.74 ± 5 MME; p < 0.001) but lower amounts of methocarbamol (759 ± 590 vs. 966 ± 585 mg; p
= 0.011). No patient requested an opioid prescription refill or presented to the emergency room secondary to pain.
Conclusion Following laparoscopic bariatric surgery, an opioid sparing discharge protocol is feasible with < 2% of patients
receiving opioids after discharge and no increase in emergency room visits. Education regarding these protocols may impact
the amount of opioids taken during hospitalization.
Keywords Opioids · Diversion · Opioid sparing protocol

Introduction
Key points
• Opioids are overprescribed after many types of surgeries.
• Diversion and dependence are potential consequences of opioid
prescribing.
• Most laparoscopic bariatric surgery patients do not take
discharge opioids.
• Discharge without opioids is feasible after laparoscopic bariatric
surgery.
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Over prescribing of opioids following surgery contributes to
the opioid crisis through diversion of pills and the potential
for new persistent opioid use. Most patients who fill opioid
prescriptions after a surgical procedure report that a portion
of their pills goes unused [1]. Furthermore, 75% of patients
admitted that their pills were not stored in a secure location
or safely disposed of, which contributes to the abundance of
prescription drugs that are used for nonmedical purposes.
This can be unsafe and even lethal [1].
It has been reported that after both minor and major
surgical procedures, the rates of new persistent opioid
use are similar [2]. Morbid obesity and bariatric surgery
may both be independent risk factors for opioid use [3, 4].
One year following bariatric surgery, Smith et al. found
that 6.3% of opioid-naïve patients became new persistent
opioid users which was associated with worse outcomes
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including decreased weight loss, decreased overall satisfaction, and less improvement in body image and depression
[5]. Enhanced recovery after surgery (ERAS) programs have
been implemented for multiple procedures to reduce length
of stay and optimize outcomes. One strategy to facilitate
these goals is to limit the use of narcotics while providing
alternate nonopioid analgesic medications for pain control.
However, there is a paucity of information and no defined
consensus in the literature regarding opioid prescribing following bariatric surgery.
Despite limiting the amount of discharge opioids prescribed to our bariatric surgery patients to five pills and only
to those patients who requested a prescription, we found
that less than half of these patients took any opioids and
less than a quarter of the total pills prescribed were actually
consumed [6]. Based on these findings, we were interested in
further reducing our discharge opioid prescribing and were
curious if this was practical. Thus, our aim in this study
was to determine the feasibility of implementing an opioid
sparing discharge protocol in minimally invasive bariatric
surgery patients.

Methods
We performed a retrospective cohort study at a single institution. Institutional review board approval was obtained
prior to collecting any data. This included a chart review
of 212 opioid-naïve patients undergoing either laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-enY gastric bypass (LGB). These patients were subsequently
divided into two groups; 106 prior to (Cohort A) and 106
after implementation (Cohort B) of an opioid-free discharge
protocol between 7/1/2019 and 2/9/2021. Patients using opioids preoperatively within 90 days of surgery were excluded
from this study. Prior opioid use was verified via the medical
record and by examining the Michigan Automated Prescription Service (MAPS) to check for filled opioid prescriptions.
Patients who did not attend their 2-week follow-up appointment were excluded.
Each patient in both cohorts was part of an ERAS
protocol which included preoperative education and
multimodal pain management in the perioperative period
including intraoperative bilateral transversus abdominis
plane (TAP) blocks. Both cohorts were provided
preoperative education about the risks of opioid use
and our discharge protocol of receiving routine nonopioid analgesics for pain management. Those in Cohort
A were educated about the option to receive discharge
opioids and those in Cohort B were educated about
not receiving discharge opioids. Our ERAS protocol,
operative technique, and order sets were unchanged
between cohorts. In the preoperative care unit, celecoxib

13

and dexamethasone were given. A total of 90 mL of 0.25%
bupivacaine was utilized per patient during the bilateral
TAP block and an additional 30 mL of 0.25% bupivacaine
was injected intraperitoneally in the subdiaphragmatic
space in the left upper quadrant. Intraoperative anesthesia
included lidocaine, ketamine, and dexmedetomidine
and acetaminophen was infused at the conclusion of
the operation. Postoperatively scheduled celecoxib and
acetaminophen and as needed methocarbamol were
utilized for pain management. Methocarbamol relaxes
skeletal muscles and is postulated to alter the perception
of pain. By suppressing the central nervous system, it
likely exerts its effects on muscle through its ability
to suppress muscle spasm, increasing mobility and
decreasing pain.
Postoperative opioids taken in the inpatient setting were
recorded in morphine milligram equivalents (MME). As
an example, 1 tablet of 5 mg oxycodone converts to 7.5
MME. They were given to patients at the discretion of
nurses on the floor with reference to the “Numerical Pain
Rating Scale,” with administration only for a score of
seven or above when there was breakthrough pain after
non-opioid analgesics were given. Each patient in Cohort
A was offered a prescription for five pills of 5 mg oxycodone at time of discharge. Patients in Cohort B were not
offered or given a prescription for opioid medication. All
patients were given prescriptions for celecoxib and acetaminophen upon discharge. The amount of each medication
taken at home was obtained and recorded by our registered
dietitian at the patient’s 2-week postoperative follow-up
appointment.
Demographics and comorbidities including age, gender,
race, body mass index (BMI), hypertension, hyperlipidemia,
diabetes mellitus, obstructive sleep apnea, arthritis, and
degenerative disk disease were examined. Operative time
and length of stay were compared between cohorts, as well
as inpatient and outpatient opioid medication consumption.
Inpatient methocarbamol and outpatient celecoxib and acetaminophen were recorded. It was also noted if any patients
requested a refill of an opioid medication or visited the emergency department secondary to complaints of pain. All opioid prescriptions were verified using the MAPS system.
Between-cohort comparisons of categorical variables
were made using the chi-square test for association or Fisher’s exact test. In numerical data where the conditions for
parametric analysis could be assumed, comparisons were
made using the t test and where the conditions for parametric analysis could not be assumed, comparisons were made
using the Mann-Whitney U test. Correlations were calculated as Spearman’s rho. Data are presented as means with
standard deviations. Throughout this study, a p-value ≤ 0.05
(two-tail) was considered statistically significant. Following
initial data entry using Microsoft Excel, Minitab version 19
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Statistical Software (State College, PA) or Langsrud on-line
calculator (http://www.langsr ud.com/fisher.htm) was used
for performing the analyses.

Results
A total of 237 total patients were originally evaluated in
this study and 25 patients were excluded due to preoperative opioid use as noted in the medical record or MAPS.
The majority of patients were female (88%), and the average
preoperative BMI was 46.8. There were no significant differences in characteristics between cohorts (Table 1).
Cohort A received more opioid prescriptions (58)
upon discharge than Cohort B (0) (p < 0.00001, CI 95%).
In Cohort A, 53 patients filled the prescription that they
received (91%). Overall, Cohort A took greater amounts of
opioids than Cohort B during hospitalization (6.92 ± 10.77
vs. 2.74 ± 5.0 MME; p < 0.01) and after discharge (4.74 ±
11 vs. 0.21 ± 2 MME; p < 0.001) (Fig. 1). Post-discharge
usage of celecoxib and acetaminophen was both higher
in Cohort B but not significantly different than Cohort A
(Fig. 2). Only two of the 212 patients (0.9%) in our entire
Table 1  Characteristics between cohorts
Cohort A

Cohort B

p-value

Age, mean ± SD
43.8 ± 11.3 43.6 ±10.3
0.899
Sex, n (%)
Female
94 (88.7)
93 (87.7)
0.831
Male
12 (11.3)
13 (12.3)
Race, n (%)
White
74 (69.8)
66 (62.3)
0.207
Non-white
31 (30.2)
40 (37.8)
46.4 ± 6.8
0.551
Preoperative BMI (body mass 47.2 ± 7.1
index, kg/m2), mean ±SD
Weight kg, mean ± SD
120.9 ± 23.8 124.4 ± 23.2 0.278
Comorbidities, n (%)
HTN
52 (49.1)
50 (47.2)
0.783
HLD
48 (45.3)
56 (52.8)
0.272
DM
36 (34.0)
30 (28.3)
0.373
OSA
46 (43.4)
39 (36.8)
0.327
Arthritis
29 (27.4)
37 (34.9)
0.235
DDD
8 (0.8)
4 (0.4)
0.374
Type of operation, n (%)
LSG
88 (83)
65 (61.3)
< 0.001
LGB
18 (17)
41 (38.7)
Operative time, mean (min)
83.0 ± 32.2 105.6 ± 39.7 < 0.001
± SD
LOS days, n (%) **excluding 3 day stays in both cohorts because n
was so small
1
92 (86.8)
97 (91.5)
0.165
2
13 (13.2)
7 (8.5)

Fig. 1  Mean amount of opioids taken in each cohort as an inpatient
and outpatient (MME)

study called our office and requested a post-discharge opioid
prescription. One of these patients called on postoperative
day number three with pain at the gastrectomy and cholecystectomy extraction trocar site. The other patient called on
postoperative day number 21 with gastrectomy extraction
trocar site burning pain exacerbated with movement. Both
of these patients were in Cohort B and were not given an
opioid prescription upon discharge. No patients requested
an opioid prescription refill or presented to the Emergency
Department because of pain.
Pre-operative BMI (47.2 ± 7.1 vs. 46.4 ± 6.8; p = 0.55)
and length of stay (1.12 +/–0.33 vs. 1.07 +/–0.25; p =
0.165) were similar between cohorts. There was a higher
number of LGB operations as compared to LSG operations
in Cohort B (Cohort A 88 LSG and 18 LGB versus Cohort
B 65 LSG and 41 LGB; p < 0.01) with a corresponding
longer mean operative time in Cohort B (83.0 ± 32.2 vs.
105.6 ± 39.7 min; p < 0.01). Cohort A used more opioids
in the PACU (1.14 ± 1.61vs.0.18 ± 0.51MME; p < 0.01) as
well as throughout their entire hospital stay in comparison
to Cohort B. Patients in Cohort B used significantly more
methocarbamol in the hospital in comparison to patients in
Cohort A (759 ± 591 mg vs. 966 ± 585; p < 0.011) (Fig. 3).

Discussion
This study demonstrates that it is feasible to discharge patients
without an opioid prescription following laparoscopic bariatric
surgery. Only two patients (1.3%) in our entire study population
who did not receive a discharge opioid prescription contacted
our office for opioids to further manage their pain. Greater
amounts of celecoxib and acetaminophen were used after
discharge in patients not receiving an opioid prescription
although this did not reach statistical significance. Interestingly,
adoption of our opioid sparing discharge protocol was associated
with a reduction in postoperative inpatient opioid use.
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Fig. 2  Mean amount of
celecoxib and acetaminophen
consumed as an outpatient (mg)

Fig. 3  Mean amount of methocarbamol use as an inpatient (mg)

There is currently no consensus and a paucity of
information regarding the appropriate amount of opioids
to prescribe postoperatively upon discharge in laparoscopic bariatric surgery patients. One study describes an
appropriate amount should be limited to 15 opioid pills
based on average number of pills prescribed and used in
their population [7]. Another resource that describes a
possible guideline is the Michigan Opioid Prescription
Engagement Network (M-OPEN). M-OPEN provides
recommendations for discharge opioid prescribing for a
variety of surgical procedures established by evidencedbased literature or expert opinion when a lack of evidence exists [8]. The recommendation for LSG is based
on expert opinion and is 0–10 5-mg tablets of oxycodone.
Laparoscopic sleeve gastrectomy patients in our study
used on average less than one 5-mg oxycodone pill to
manage their pain adequately after leaving the hospital.
This demonstrates the wide range of recommendations
and potential for overprescribing opioid medication in
the laparoscopic bariatric surgery population.
As previously mentioned, opioid-naïve patients are
vulnerable to developing new persistent opioid use or
chronic opioid use after surgery. Chronic opioid use has
been shown to be more common in patients requiring
opioid prescriptions upon discharge than patients who
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did not receive a prescription after an inpatient hospital
stay [9]. Brummett et al. identified the incidence of new
persistent opioid use between 3 and 6 months to range
between 5.9 and 6.5% following minor and major surgical procedures whereas the nonoperative control cohort
incidence was only 0.4% [2]. Different risk factors have
been described in opioid dependance including tobacco
use, chronic pain, mood disorders, anxiety, and alcohol
abuse [2]. Patients in the bariatric surgery population
have an increased incidence of these risk factors [4],
making them at higher risk for postoperative opioid use.
It has also been shown that new persistent opioid use
following bariatric surgery is significantly associated
with other detrimental effects such as decreased satisfaction, worse psychological well-being, and lower percent
excess body weight loss [5]. The vulnerability of this
population makes utilizing an opioid sparing discharge
protocol enticing with the potential to limit the number
of new persistent or chronic opioid users with improvement in overall outcomes.
A study evaluating the source of prescription
medication misuse described that 50% of misusers
endorsed receiving the medication from a family or
relative for free [10]. It has also been reported that unused
narcotics are typically kept in unsecure locations and
are not disposed of in an appropriate manner [1]. This
raises the concern of opioid diversion when prescription
medication goes unused. In our study, 58 prescriptions of
five pills of 5-mg oxycodone were given in Cohort A with
53 of them being filled, equating to 265 pills available for
use. The total number of pills actually consumed in Cohort
A was 67, leaving 198 pills (75%) unused. By reducing
the number of opioids prescribed upon discharge, we can
reduce the number of pills that are available for opioid
diversion. Because nearly all of the patients in Cohort
B did not call the office complaining of pain, request an
opioid prescription to manage their pain, or present to
the emergency room due to pain, we believe it is feasible
to limit the amount of discharge opioids prescribed. In
addition, these results should mitigate concerns about
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having to answer multiple patient calls to the surgeon’s
office because of pain.
Setting patient expectations preoperatively is an important
step in limiting the amount of opioids used postoperatively. It
has been described that patients who received preoperative education regarding preparation for postoperative pain management
used only half the quantity of pain pills as patients who did not
receive this preoperative education [11]. This concept has been
demonstrated for multiple surgical procedures. Each patient
in both cohorts received extensive education regarding their
postoperative course, including what to expect regarding postoperative pain management and the potential risks of opioids.
The patients in Cohort A were provided education regarding
the option for discharge opioids while those in Cohort B were
provided education about our opioid sparing discharge protocol.
We identified a surprising and unexpected effect of implementing our opioid sparing discharge protocol which was that these
patients utilized less opioids and more methocarbamol during
their hospital stay. We believe this was secondary to our targeted
education of the opioid sparing discharge protocol and commitment to this protocol to reduce the risks of new persistent and
chronic opioid use. This likely impacted patients’ decision-making which led to a preferential increase use of methocarbamol
and reduction in opioid use postoperatively. Multimodal pain
control has been proven to significantly decrease the number
of opioid medications used in the postoperative period [12].
Our protocol utilizes medications including methocarbamol,
celecoxib, and acetaminophen, as well as intraoperative TAP
blocks with bupivacaine, to optimize pain control while limiting the use of narcotics. We believe these types of strategies
are critical to support an opioid sparing discharge protocol in
bariatric surgery patients.
This study has several limitations. All patients included in
this study underwent laparoscopic surgery at a single institution
performed by the same surgeon utilizing a multimodal analgesia
ERAS pathway which may not be generalizable. The retrospective
nature of the data collection and non-contemporaneous study
groups introduces potential bias although no differences in patient
selection, surgical technique, or order sets were introduced during
the study period. Over 80% of our patients were female, which
is consistent with the national average of patients undergoing
bariatric surgery [13]. Since male gender may be an independent
risk factor for chronic opioid use after surgery [14], our study may
not reliably predict postoperative opioid discharge requirements
in male patients. However, no differences in opioid consumption
based on gender were identified.

Conclusion
An opioid sparing discharge protocol in laparoscopic bariatric surgery patients is feasible and appears to adequately
manage postoperative pain. Less than 2% of patients

discharged without opioids called the office due to concerns
about pain and requested an opioid prescription. An opioid
sparing discharge protocol has the potential to eliminate
diversion and reduce new persistent opioid use with its subsequent associated negative outcomes following bariatric
surgery.
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